| A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia S Gröschel, MA Sanders, R Hoogenboezem, E de Wit, BAM Bouwman, ... Cell 157 (2), 369-381, 2014 | 753 | 2014 |
| Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes PD Johann, S Erkek, M Zapatka, K Kerl, I Buchhalter, V Hovestadt, ... Cancer cell 29 (3), 379-393, 2016 | 558 | 2016 |
| Active medulloblastoma enhancers reveal subgroup-specific cellular origins CY Lin, S Erkek, Y Tong, L Yin, AJ Federation, M Zapatka, P Haldipur, ... Nature 530 (7588), 57-62, 2016 | 425 | 2016 |
| High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities S Groeschel, S Lugthart, RF Schlenk, PJM Valk, K Eiwen, C Goudswaard, ... Journal of Clinical Oncology 28 (12), 2101-2107, 2010 | 298 | 2010 |
| Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia S Lugthart, S Gröschel, HB Beverloo, S Kayser, PJM Valk, ... Journal of clinical oncology 28 (24), 3890-3898, 2010 | 295 | 2010 |
| Integrative genomic and transcriptomic analysis of leiomyosarcoma P Chudasama, SS Mughal, MA Sanders, D Hübschmann, I Chung, ... Nature communications 9 (1), 144, 2018 | 272 | 2018 |
| Precision oncology based on omics data: the NCT Heidelberg experience P Horak, B Klink, C Heining, S Gröschel, B Hutter, M Fröhlich, S Uhrig, ... International journal of cancer 141 (5), 877-886, 2017 | 182 | 2017 |
| Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid … S Groeschel, RF Schlenk, J Engelmann, V Rockova, V Teleanu, ... Journal of clinical oncology 31 (1), 95-103, 2013 | 127 | 2013 |
| Vascular dendritic cells in giant cell arteritis CM Weyand, WEI MA‐KRUPA, O Pryshchep, S Gröschel, R Bernardino, ... Annals of the New York Academy of Sciences 1062 (1), 195-208, 2005 | 115 | 2005 |
| Mutational spectrum of myeloid malignancies with inv (3)/t (3; 3) reveals a predominant involvement of RAS/RTK signaling pathways S Gröschel, MA Sanders, R Hoogenboezem, A Zeilemaker, M Havermans, ... Blood, The Journal of the American Society of Hematology 125 (1), 133-139, 2015 | 110 | 2015 |
| Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274)–associations with gene expression, mutational load, and survival J Budczies, M Bockmayr, C Denkert, F Klauschen, S Gröschel, ... Genes, Chromosomes and Cancer 55 (8), 626-639, 2016 | 106 | 2016 |
| An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation R Avellino, M Havermans, C Erpelinck, MA Sanders, R Hoogenboezem, ... Blood, The Journal of the American Society of Hematology 127 (24), 2991-3003, 2016 | 87 | 2016 |
| Defective homologous recombination DNA repair as therapeutic target in advanced chordoma S Gröschel, D Hübschmann, F Raimondi, P Horak, G Warsow, M Fröhlich, ... Nature communications 10 (1), 1635, 2019 | 80 | 2019 |
| Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification S Gröschel, M Bommer, B Hutter, J Budczies, D Bonekamp, C Heining, ... Molecular Case Studies 2 (6), a001180, 2016 | 74 | 2016 |
| Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling M Kordes, M Röring, C Heining, S Braun, B Hutter, D Richter, C Geörg, ... Leukemia 30 (4), 937-946, 2016 | 66 | 2016 |
| PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma J Budczies, G Mechtersheimer, C Denkert, F Klauschen, SS Mughal, ... Oncoimmunology 6 (3), e1279777, 2017 | 61 | 2017 |
| The clinical picture of cachexia: a mosaic of different parameters (experience of 503 patients) S Schwarz, O Prokopchuk, K Esefeld, S Gröschel, J Bachmann, ... BMC cancer 17, 1-10, 2017 | 57 | 2017 |
| TLR-mediated induction of negative regulatory ligands on dendritic cells S Gröschel, KD Piggott, A Vaglio, W Ma-Krupa, K Singh, JJ Goronzy, ... Journal of Molecular Medicine 86, 443-455, 2008 | 49 | 2008 |
| The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops S Ottema, R Mulet-Lazaro, C Erpelinck-Verschueren, S van Herk, ... Nature Communications 12 (1), 5679, 2021 | 47 | 2021 |
| Targeting fibroblast growth factor receptor 1 for treatment of soft-tissue sarcoma P Chudasama, M Renner, M Straub, SS Mughal, B Hutter, Z Kosaloglu, ... Clinical cancer research 23 (4), 962-973, 2017 | 39 | 2017 |
Elzo de WitNetherlands Cancer InstituteGeverifieerd e-mailadres voor nki.nl